Tvardi Therapeutics (TVRD) reported a net loss of $6.5 million, or $0.69 per basic and diluted share, for the second quarter ended June 30, 2026. The company reported $15.8 million in cash, cash equivalents and short-term investments at quarter-end.
Tvardi reported topline healthy-volunteer results for its next-generation STAT3 inhibitor TTI-109 and selected ulcerative colitis as its initial disease indication. The company plans to host a KOL webinar on August 19 and expects TTI-101 Phase 1b/2 HCC topline data in the fourth quarter of 2026.
- Research and development expense was $4.0 million, compared with $5.8 million a year earlier.
- General and administrative expense was $2.6 million, compared with $3.1 million in the prior-year quarter.
- Cash, cash equivalents and short-term investments totaled $15.8 million as of June 30, 2026, versus $30.8 million as of December 31, 2025.
- Tvardi said its existing cash is expected to fund planned operations through the HCC topline readout into the third quarter of 2027.
- The company plans to initiate a TTI-109 ulcerative colitis clinical trial in 2027, subject to IND clearance and additional funding.
$TVRD Hedge Fund Activity
We have seen 23 institutional investors add shares of $TVRD stock to their portfolio, and 45 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 292,597 shares (-75.4%) from their portfolio in Q2 2026, for an estimated $555,934
- GEODE CAPITAL MANAGEMENT, LLC removed 91,989 shares (-50.4%) from their portfolio in Q2 2026, for an estimated $174,779
- STATE STREET CORP removed 63,331 shares (-65.1%) from their portfolio in Q2 2026, for an estimated $120,328
- UBS GROUP AG added 60,679 shares (+120.3%) to their portfolio in Q2 2026, for an estimated $115,290
- JANE STREET GROUP, LLC removed 47,444 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $150,871
- AQR CAPITAL MANAGEMENT LLC added 42,192 shares (+inf%) to their portfolio in Q1 2026, for an estimated $134,170
- GREAT LAKES ADVISORS, LLC removed 36,236 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $68,848
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
